Can Buying BridgeBio Pharma Inc (NASDAQ: BBIO) Still Be Worthwhile?

BridgeBio Pharma Inc (NASDAQ:BBIO) does about 1.98M shares in volume on a normal day but saw 1341123 shares change hands in Monday trading. The company now has a market cap of 4.89B USD. Its current market price is $26.14, marking an increase of 1.48% compared to the previous close of $25.76. The 52 week high reached by this stock is $44.32 whilst the lowest price level in 52 weeks is $16.62.

BridgeBio Pharma Inc (BBIO) has a 20-day trading average at $26.23 and the current price is -41.02% off the 52-week high compared with 57.28% distance from its 52-week low. The 50-day simple moving average of the closing price is $27.30 and its 200-day simple moving average is $30.16. If we look at the stock’s price movements over the week, volatility stands at 4.21%, which increases to 5.17% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.84 to suggest the stock is neutral.

The consensus objective for the share price is $49.46, suggesting that the stock has a potential upside of 47.15% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 21, 2024 when Raymond James resumed the stock to “Outperform” and issued a price target of $45. Wells Fargo initiated its price target at $58.

BridgeBio Pharma Inc (BBIO) stock is up 3.20% over the week and -6.64% over the past month. Its price is -35.25% year-to-date and 53.76% over the past year.

To reach the target analysts have set, the stock logically needs to grow 47.15 percent from here.

The company has a return on investment of -79.78%. The beta has a value of 1.06. Price to sales ratio is 22.38.